The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aruga, A.
Right arrow Articles by Chang, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aruga, A.
Right arrow Articles by Chang, A. E.

The Journal of Immunology, Vol 159, Issue 2 664-673, Copyright © 1997 by American Association of Immunologists

ARTICLES

Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role

A Aruga, E Aruga, K Tanigawa, DK Bishop, VK Sondak and AE Chang
Department of Surgery, University of Michigan, Ann Arbor 48109, USA.

We have previously reported that CD8+ tumor-draining lymph node (TDLN) cells activated with anti-CD3 and IL-2-mediated tumor regression in adoptive immunotherapy. In this study, we examined the TCR Vbeta repertoire usage of TDLN cells with respect to cytokine release profiles and therapeutic efficacy in vivo. The majority of the whole population of TDLN cells after activation with anti-CD3 were composed of Vbeta3+, -5+, -7+, -8+, and -11+ cells. Enrichment of Vbeta subsets of TDLN cells by in vitro activation with anti-Vbeta mAb revealed Vbeta8+ cells released high amounts of IFN-gamma and granulocyte/macrophage-CSF (GM-CSF) with minimal amounts of IL-10 in response to tumor and mediated tumor regression in vivo. In contrast, enriched populations of Vbeta5+, Vbeta7+, and Vbeta11+ cells released low amounts of IFN-gamma and GM-CSF with high levels of IL-10 and had no in vivo antitumor reactivity. In vitro depletion of specific Vbeta subsets from the whole TDLN pool confirmed that the profile of cytokines released correlated with in vivo antitumor function. Therapeutic efficacy mediated by TDLN cells required the release of IFN- gamma and GM-CSF since in vivo neutralization of both cytokines inhibited tumor regression. The administration of anti-IL-10 mAb abrogated the suppressed antitumor response manifested by adoptively transferred TDLN cells, which elaborated increased levels of IL-10. Our study documents that type 1 cytokine release (i.e., IFN-gamma and GM- CSF) promotes in vivo tumor Ag recognition, in contrast to type 2 release (i.e., IL-10), which suppresses this interaction, and discriminates the functional activity of Vbeta subpopulations of effector cells.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. Iuchi, S. Teitz-Tennenbaum, J. Huang, B. G. Redman, S. D. Hughes, M. Li, G. Jiang, A. E. Chang, and Q. Li
Interleukin-21 Augments the Efficacy of T-Cell Therapy by Eliciting Concurrent Cellular and Humoral Responses
Cancer Res., June 1, 2008; 68(11): 4431 - 4441.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. G. Elpek, C. Lacelle, N. P. Singh, E. S. Yolcu, and H. Shirwan
CD4+CD25+ T Regulatory Cells Dominate Multiple Immune Evasion Mechanisms in Early but Not Late Phases of Tumor Development in a B Cell Lymphoma Model
J. Immunol., June 1, 2007; 178(11): 6840 - 6848.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. M. Hargadon, C. C. Brinkman, S. L. Sheasley-O'Neill, L. A. Nichols, T. N. J. Bullock, and V. H. Engelhard
Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes
J. Immunol., November 1, 2006; 177(9): 6081 - 6090.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Saji, W. Song, K. Furumoto, H. Kato, and E. G. Engleman
Systemic Antitumor Effect of Intratumoral Injection of Dendritic Cells in Combination with Local Photodynamic Therapy
Clin. Cancer Res., April 15, 2006; 12(8): 2568 - 2574.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Q. Li, A. C. Grover, E. J. Donald, A. Carr, J. Yu, J. Whitfield, M. Nelson, N. Takeshita, and A. E. Chang
Simultaneous Targeting of CD3 on T Cells and CD40 on B or Dendritic Cells Augments the Antitumor Reactivity of Tumor-Primed Lymph Node Cells
J. Immunol., August 1, 2005; 175(3): 1424 - 1432.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S.-i. Hiraoka, N. Takeuchi, Y. Bian, H. Nakahara, M. Kogo, K. Dunussi-Joannopoulos, S. Wolf, S. Ono, and H. Fujiwara
B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors
Int. Immunol., August 1, 2005; 17(8): 1071 - 1079.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang
Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern
Cancer Res., February 1, 2005; 65(3): 1063 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. J. Sussman, R. Parihar, K. Winstead, and F. D. Finkelman
Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion
Cancer Res., December 15, 2004; 64(24): 9124 - 9130.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Skitzki, R. A. Craig, R. Okuyama, R. N. Knibbs, K. McDonagh, A. E. Chang, and L. M. Stoolman
Donor Cell Cycling, Trafficking, and Accumulation during Adoptive Immunotherapy for Murine Lung Metastases
Cancer Res., March 15, 2004; 64(6): 2183 - 2191.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Teitz-Tennenbaum, Q. Li, S. Rynkiewicz, F. Ito, M. A. Davis, C. J. Mcginn, and A. E. Chang
Radiotherapy Potentiates the Therapeutic Efficacy of Intratumoral Dendritic Cell Administration
Cancer Res., December 1, 2003; 63(23): 8466 - 8475.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Ullenhag, J.-E. Frodin, S. Mosolits, S. Kiaii, M. Hassan, M. C. Bonnet, P. Moingeon, H. Mellstedt, and H. Rabbani
Immunization of Colorectal Carcinoma Patients with a Recombinant Canarypox Virus Expressing the Tumor Antigen Ep-CAM/KSA (ALVAC-KSA) and Granulocyte Macrophage Colony- stimulating Factor Induced a Tumor-specific Cellular Immune Response
Clin. Cancer Res., July 1, 2003; 9(7): 2447 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Li, A. Carr, F. Ito, S. Teitz-Tennenbaum, and A. E. Chang
Polarization Effects of 4-1BB during CD28 Costimulation in Generating Tumor-reactive T Cells for Cancer Immunotherapy
Cancer Res., May 15, 2003; 63(10): 2546 - 2552.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. E. Chang, Q. Li, G. Jiang, D. M. Sayre, T. M. Braun, and B. G. Redman
Phase II Trial of Autologous Tumor Vaccination, Anti-CD3-Activated Vaccine-Primed Lymphocytes, and Interleukin-2 in Stage IV Renal Cell Cancer
J. Clin. Oncol., March 1, 2003; 21(5): 884 - 890.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Dorsey, N. Kundu, Q. Yang, C. S. Tannenbaum, H. Sun, T. A. Hamilton, and A. M. Fulton
Immunotherapy with Interleukin-10 Depends on the CXC Chemokines Inducible Protein-10 and Monokine Induced by IFN-{gamma}
Cancer Res., May 1, 2002; 62(9): 2606 - 2610.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. E. Chang, B. G. Redman, J. R. Whitfield, B. J. Nickoloff, T. M. Braun, P. P. Lee, J. D. Geiger, and J. J. Mule
A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer
Clin. Cancer Res., April 1, 2002; 8(4): 1021 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Geiger, R. J. Hutchinson, L. F. Hohenkirk, E. A. McKenna, G. A. Yanik, J. E. Levine, A. E. Chang, T. M. Braun, and J. J. Mule
Vaccination Of Pediatric Solid Tumor Patients with Tumor Lysate-pulsed Dendritic Cells Can Expand Specific T Cells and Mediate Tumor Regression
Cancer Res., December 1, 2001; 61(23): 8513 - 8519.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. E. Curiel, C. S. Garcia, L. Farooq, M. F. Aguero, and I. Espinoza-Delgado
Bryostatin-1 and IL-2 Synergize to Induce IFN-{gamma} Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy
J. Immunol., November 1, 2001; 167(9): 4828 - 4837.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Tanigawa, N. Takeshita, R. A. Craig, K. Phillips, R. N. Knibbs, A. E. Chang, and L. M. Stoolman
Tumor-Specific Responses in Lymph Nodes Draining Murine Sarcomas Are Concentrated in Cells Expressing P-Selectin Binding Sites
J. Immunol., September 15, 2001; 167(6): 3089 - 3098.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Winter, H.-M. Hu, K. McClain, W. J. Urba, and B. A. Fox
Immunotherapy of Melanoma: A Dichotomy in the Requirement for IFN-{{gamma}} in Vaccine-Induced Antitumor Immunity Versus Adoptive Immunotherapy
J. Immunol., June 15, 2001; 166(12): 7370 - 7380.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Winter, H.-M. Hu, W. J. Urba, and B. A. Fox
Tumor Regression After Adoptive Transfer of Effector T Cells Is Independent of Perforin or Fas Ligand (APO-1L/CD95L)
J. Immunol., October 15, 1999; 163(8): 4462 - 4472.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. M. Kalergis, T. Ono, F. Wang, T. P. DiLorenzo, S. Honda, and S. G. Nathenson
Single Amino Acid Replacements in an Antigenic Peptide Are Sufficient to Alter the TCR V{beta} Repertoire of the Responding CD8+ Cytotoxic Lymphocyte Population
J. Immunol., June 15, 1999; 162(12): 7263 - 7270.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, and R. W. Dutton
Therapeutic Effects of Tumor-Reactive Type 1 and Type 2 CD8+ T Cell Subpopulations in Established Pulmonary Metastases
J. Immunol., June 1, 1999; 162(11): 6671 - 6680.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. G. Chakraborty, L. Li, J. R. Sporn, S. H. Kurtzman, M. T. Ergin, and B. Mukherji
Emergence of Regulatory CD4+ T Cell Response to Repetitive Stimulation with Antigen-Presenting Cells In Vitro: Implications in Designing Antigen-Presenting Cell-Based Tumor Vaccines
J. Immunol., May 1, 1999; 162(9): 5576 - 5583.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. K. Halak, H. C. Maguire Jr., and E. C. Lattime
Tumor-induced Interleukin-10 Inhibits Type 1 Immune Responses Directed at a Tumor Antigen As Well As a Non-Tumor Antigen Present at the Tumor Site
Cancer Res., February 1, 1999; 59(4): 911 - 917.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Li, S. A. Furman, C. R. Bradford, and A. E. Chang
Expanded Tumor-reactive CD4+ T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation
Clin. Cancer Res., February 1, 1999; 5(2): 461 - 469.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H.-M. Hu, W. J. Urba, and B. A. Fox
Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile
J. Immunol., September 15, 1998; 161(6): 3033 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Prevost-Blondel, C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher
Tumor-Infiltrating Lymphocytes Exhibiting High Ex Vivo Cytolytic Activity Fail to Prevent Murine Melanoma Tumor Growth In Vivo
J. Immunol., September 1, 1998; 161(5): 2187 - 2194.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.